Related Experiment Video
Updated: Sep 16, 2025
03:45
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
3.7K
Mid-Cavitary Obstruction in Hypertrophic Cardiomyopathy (HCM): A Rare Case Report and Management Approach.
Rajeev Bharadwaj1, Deb Boruah1, Bhupen Barman1
1All India Institute of Medical Sciences, Guwahati, India.
Acta Medica Lituanica
|July 11, 2025
Summary
Hypertrophic cardiomyopathy with mid-cavitary obstruction (MCO) is a serious condition. Early recognition and conservative beta-blocker therapy can improve symptoms in patients with MCO.
Area of Science:
- Cardiology
- Cardiovascular Medicine
- Medical Case Reports
Background:
- Hypertrophic cardiomyopathy (HCM) affects approximately 10% of patients with mid-cavitary obstruction (MCO).
- MCO is linked to severe outcomes, including sudden cardiac death and heart failure.
- Patients with MCO face risks of apical aneurysms, thromboembolism, and arrhythmias.
Purpose of the Study:
- To present a case of hypertrophic cardiomyopathy with mid-cavitary obstruction.
- To discuss the diagnosis and management of this uncommon condition.
- To highlight unique treatment considerations for MCO.
Main Methods:
- Case presentation of a 43-year-old male with type 2 diabetes mellitus.
- Diagnosis confirmed via cardiac MRI with gadolinium contrast, revealing significant MCO without left ventricular outflow tract obstruction.
- Assessment of scar burden and absence of other high-risk factors.
Main Results:
- The patient presented with dyspnea and palpitations.
- Cardiac MRI showed significant mid-cavitary obstruction (27% scar burden) but no left ventricular outflow tract obstruction.
- Conservative treatment with oral beta-blockers led to symptomatic improvement.
Conclusions:
- Early recognition of MCO in HCM is crucial for appropriate management.
- Conservative beta-blocker therapy can be effective in improving symptoms.
- Personalized treatment is essential given the high-risk nature of MCO.
Keywords:
beta-blocker therapyconservative managementheart failurehypertrophic cardiomyopathyleft ventricle outflow tract obstructionmid-cavitary obstructionrisk stratificationMore Related Videos
14:39Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
Published on: April 21, 2014
17.5K
08:42Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China
Published on: February 11, 2022
3.6K
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
61
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
61
01:29Cardiomyopathy V: Interprofessional Care
38
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
38
01:28Cardiomyopathy VII: Pre and Post Operative Nursing Management
29
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
29
01:25Cardiomyopathy I: Introduction and Classification
71
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
71
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
39
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
39
01:30Cardiomyopathy II: Dilated Cardiomyopathy
30
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
30